NCT06361563已完成不适用
Patients With Upper Gastrointestinal Cancer Enrolled in a Patient Support Program to Receive Nivolumab in the Adjuvant Setting: Real World Data From Canada
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2023年9月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Participant primary upper gastrointestinal cancer diagnosis
研究概览
简要总结
The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Enrolled in Bristol-Myers Squibb GastroEsophageal Opdivo in Resected Patients with Residual Pathological Disease Patient Support Program (GEORge PSP) in Canada
- •Patients who have consented to the use of their de-identified data generated from information collected in the course of the GEORge PSP
排除标准
- •Aged <18 years
- •Did not receive concurrent chemoradiotherapy prior to surgery
- •Positive margins following resection
- •No residual disease following complete resection
研究组 & 干预措施
Participants treated with adjuvant nivolumab
干预措施: Nivolumab (Drug)
结局指标
主要结局
Participant primary upper gastrointestinal cancer diagnosis
时间窗: Baseline
Participant comorbidities
时间窗: Baseline
Date of tumour resection
时间窗: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) score
时间窗: Baseline
Participant tumour location
时间窗: Baseline
Participant sociodemographics
时间窗: Baseline
Participant histology results
时间窗: Baseline
次要结局
- Number of nivolumab treatments received(Up to 484 days)
- Participant adverse events (AEs)(Up to 484 days)
- Initial nivolumab dosage prescribed to participants(Index date)
- Nivolumab treatment duration(Up to 484 days)
- Nivolumab dosage modification(Up to 484 days)
- Reason for participant discharge(Up to 484 days)
- Management of participant adverse events (AEs)(Up to 484 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in CanadaUpper Gastrointestinal CancerNCT06361576Bristol-Myers Squibb700
尚未招募
不适用
Prospective Observational Cohort StudyLiver MetastasesGastric CancerNCT06493448Lin Chen1,326
撤回
不适用
Electronic Patient Reported Outcomes in Patients With Gastrointestinal CancersGastrointestinal CancersGastrointestinal Cancer MetastaticNCT05359042University of California, San Francisco
进行中（未招募）
不适用
GastroIntestinal Cancer in Children and AdolescentsGastrointestinal CancerBurkitt LymphomaNeuroendocrine TumorsHepatocellular CarcinomaGastric CancerHepatoblastomaColorectal CancerNCT05693519Paul G. Kemps, MD2,500
招募中
不适用
A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing MethodOrganoidsGastric CancerNCT06100003Funan Liu104